• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WIRB-Copernicus Group appoints Lindsay McNair chief medical officer

WIRB-Copernicus Group appoints Lindsay McNair chief medical officer

October 3, 2014
CenterWatch Staff

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, has promoted Lindsay McNair, M.D., M.P.H., M.S.B., to chief medical officer.

“As a physician, clinical investigator, consultant and former academic institutional review board (IRB) member, Dr. McNair brings her extensive experience of both drug development and the ethical oversight of research to our organization,” said Donald A. Deieso, Ph.D., WCG chairman and CEO. “With this powerful background, Dr. McNair will support WCG’s clinical professionals and clients in making decisions that create efficient and effective clinical development programs that respect and protect the well-being of clinical trial participants.”

McNair will guide the activities of more than 50 clinicians including physicians, nurses and biosafety experts. She has more than 15 years’ experience providing medical guidance on clinical development strategies and study designs for new drugs. In previous roles in the pharmaceutical industry, she has delivered medical oversight for all phases of clinical studies in a variety of therapeutic areas, including multiple oncology indications, hepatitis C, psoriasis and multiple sclerosis. In addition, Dr. McNair provides ethical guidance, having founded the Human Subject Protection Committee at Vertex Pharmaceuticals.

McNair is an adjunct associate professor at the Boston University School of Public Health, and was a member of the Boston University Medical Center IRB. She also is a member of The World Council for Ethical Standards; the Ethical Protocol Development Committee at the Multi-Regional Clinical Trials (MRCT) Center, which is administered by Harvard; the ethics committee for Care Dimensions, formerly known as the Hospice of North Shore and Greater Boston; and Public Responsibility in Medicine and Research (PRIM&R).

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing